People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cavalry Management Aggregator Llc | — | Other | Series B | $30.0M | $306.2M | 2022 |
| Dracen Pharmaceuticals, Inc. | — | Biotechnology | Series A | $19.4M | $20.0M | 2018 |
Robert M. Jackson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert M. Jackson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eric Schwartz | 1 | 7 |
| Thomas M. Estok | 1 | 3 |
| Asher M. Rubin | 1 | 2 |
| Jonathan M. Leff | 1 | 1 |
| Brent M. Behrman | 1 | 1 |
| John M. Hatem | 1 | 1 |
| Katherine M. Motlagh | 1 | 1 |
| Matthew M. Pullen | 1 | 1 |
| Drew M. Pardoll, M.D., Ph.D. | 1 | 1 |
| Dennis M. Bilski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.